Nextgensit: an off-the-shelf and on-demand product for biological control of aedes aegypti mosquitoes - the overarching objective of this project is to finalize the development and commercialization…

Nextgensit: an off-the-shelf and on-demand product for biological control of aedes aegypti mosquitoes - the overarching objective of this project is to finalize the development and commercialization of synvect's innovative nextgensit technology for aedes aegypti mosquito control. This transformative genetic engineering solution combines precision-guided crispr gene knockouts with scalable deployment methods to address the urgent global need for ECO-friendly, effective, and cost efficient mosquito control. By targeting mosquito populations responsible for spreading diseases such as dengue, yellow fever, and zika, this project aims to establish a new standard for combating vector-borne diseases while advancing regulatory readiness and market viability. Aim 1 focuses on finalizing the genetic components for the AE. Aegypti nextgensit eggs, leveraging crispr-mediated knockouts of specific genes to ensure the production of competitive, sterile males at scale. This work involves rigorous testing and optimization to select the most effective genetic reagents for deployment. Aim 2 emphasizes developing and validating deployment strategies for nextgensit eggs. This includes optimizing the EGG-to-male transformation in the environment by deploying the produced eggs and reusable EGG-to-adult boxes to create a user-friendly and cost-effective product for large-scale application. Aim 3 transitions from laboratory validation to semi-field and small-scale open-air pilots in florida and texas, assessing deployment parameters and achieving a 90% reduction in mosquito populations under controlled yet realistic conditions. These interim trials will bridge the GAP between lab results and real-world deployment, providing critical data on scalability, environmental adaptability, and operational efficacy. Aim 4 expands on this foundation by conducting larger open-air pilots with government and commercial partners, validating the real-world impact of nextgensit and securing the environmental protection agency (EPA) approval. This phase is critical for demonstrating product value, aligning with customer needs, and converting at least 50% of pilot participants into long-term customers. The expected outcomes of this project include the development of a scalable, ECO-friendly mosquito control solution with proven efficacy in reducing vector populations, securing EPA approval, and establishing synvect as a trusted leader in vector control technologies. By bridging lab innovation with real-world application, this initiative will create a robust pathway for commercialization and set a new benchmark in combating vector-borne diseases globally.